Qian Z, et al. - Researchers focused on the potential role of Prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in esophageal squamous cell carcinoma (ESCC). In 77 frozen ESCC samples, they assessed PRAF2 mRNA expression via quantitative reverse transcription-polymerase chain reaction. They assessed the link of PRAF2 mRNA expression with clinical characteristics and overall survival. ESCC tissues vs matched surrounding non-tumor tissues exhibited significantly increased PRAF2 mRNA expression. Worse overall survival was reported in relation to high PRAF2 mRNA expression. In ESCC, poor overall survival was independently predicted by PRAF2, as revealed in multivariate analysis. As a result of knockdown of PRAF2 expression, cell proliferation, cell cycle progression, and cell invasion were blocked and cell apoptosis was triggered in ESCC cells, as revealed in the in vitro experiments. Overall, PRAF2 could serve as a potential prognostic biomarker and is a potential therapeutic target for ESCC.